Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption. Sophia Humphreys, ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...

Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...

Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference ...

Number 5: By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely ...

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and ...

Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...